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Introduction
Vaccination  strategies  are  one  of  the  most
powerful  interventions  in  the  field  of  Public
Health  worldwide,  both  in  reducing  morbidity
and  mortality.  Vaccination  implementation  is  a
proven tool for controlling and even eradicating
disease  and World  Health  Organisation  (WHO)
estimates  that  immunization  averted
approximately two million deaths in 2002 [1]. At
the  global  level  it  has  been  calculated  that
infectious diseases are still responsible for about
one quarter of the overall mortality, particularly in
children aged younger than 5 years [2].
Several  new  vaccines  with  major  potential  for
controlling infectious diseases are now available,
thanks to the development of new prophylactic
vaccines  against  many  acute  infectious  diseases
that  have  an  important  burden  of  disease.
Moreover, further vaccines  will be available in the
next few years, and this will be a critical point for
decision makers, because of the large number of
vaccines available by 2015 [3].
Despite the potential availability of vaccines, we
are pretty sure that according to limited economic
health  resources,  the  Governments  will  not  be
able  to  finance  all  vaccines  produced  by  drug
companies. This issue implies that it will more and
more  important  in  the  near  future  in  deciding
how to better  allocate resources, especially in the
field of public health interventions. 
This  paper  aims  to  describe  the  different
perspectives from which it is possible to evaluate
vaccines,  and  in  particular  new  vaccines.  It
considers  the  following  approaches:  a)
epidemiological;  b)  health  economic;  c)  public
perspective;  d)  health  technology  assessment
(HTA). 
The Epidemiological approach
The  decisions  on  the  introduction  of  a  new
vaccine in the immunisation schedule of a certain
country is first of all based on the assessment of
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Abstract
Vaccination strategies are recognised as one of the most powerful interventions in the field of Public health
worldwide, capable of reducing both morbidity and mortality. There is wide availability of new vaccines, at
least in Developed Countries, that have the potential to control infectious diseases, while on the other hand
there are new vaccines that will become available in the next few years. This paper aims to describe the
different perspectives one could take into account in valuing particularly new vaccines.
The epidemiological approach has been one of underlying principles in setting priorities  for immunization
programs. The introduction in the health market of a new vaccine is based on the assessment of the related
burden of infection/disease and the consequent impact on population health.  
In the economic evaluation approach several types of analysis are available. The budget impact analysis is
concerned more with the immediate impact; in this sense cost is considered instead of value as well as giving
higher consideration to short-term effects, while cost-effectiveness or cost-utility analysis can be utilised to
examine effects in the long term.
In the field of vaccinations a public approachthrough the use of media campaigns or non-profit organisations,
might or might not push politicians and physicians to take action to address a perceived health problem via
a vaccine. 
A Health Technology Assessment approach has been developed in some European countries to examine, in a
multidisciplinary way, the clinical, economic, organizational, ethical, juridical, social and cultural implications
of  the  introduction  or  the  implementation  of  a  specific  technology.  The  HTA  approach  in  Italy  was
demonstrated to be a comprehensive tool in assessing the introduction of a new vaccine, giving insight to the
issue to several stakeholders, i.e. decision makers, researchers, and patients.  
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the related burden of  infection/disease and the
consequent  impact  on  the  population’s  health.
Incidence rate of the infection/disease, mortality
rate,  permanent  sequelae,  complications  and
related  hospitalisations  are  usually  the  main
elements that are considered. [4]. 
Moreover, this approach aims to also take into
consideration issues such as information on the
vaccine safety and effectiveness that are topics to
address in suggesting priorities for policy makers.
The epidemiological approach has been seen for
several years as one of the main factors in setting
priorities  for  vaccines  to  be  introduced  into
immunization programs [5]. The underlined idea
is that the higher the burden, the more attractive
a potential addition to the immunization schedule
of  a  specific  country  would  be  in  the  view  of
decision makers.
Vaccine safety and performance in this context
are  also  important  issues.  Most  countries  have
mentioned  safety,  low  rates  of  side  effects  and
vaccine performance as fundamental elements to
consider  when  introducing  a  new  vaccine,
especially in developing countries [6].
The economic evaluation approach
The economic impact of an infectious disease is
another  key  issue  to  be  considered  in  the
evaluation of the implementation of a vaccine in a
specific country. Information on the potential cost
savings determined by vaccine coverage is critical
in order to convince the decision makers of the
opportunity of financing a vaccine campaign. 
Based  on  this  perspective,  several  types  of
economic  evaluation  are  available.  The  Budget
Impact  analysis  is  concerned  more  about  the
immediate impact, in the sense that it considers
cost  instead  of  value.  In  this  view,  little
consideration is given to long-term effects [7]. 
Decision  makers  now  consider  cost
effectiveness  analysis  (CEA)  as  one  of  the  key
factors  for  adding  a  new  vaccine  into  national
immunization programmes versus an alternative
use of the resources [8]. 
However, CEA is far from perfect, as there has
been  a  number  of  times  when  an  explicit
statement on key elements of the analysis has not
been  given. A  recent  systematic  review  of  the
economic analyses of HPV vaccine was conducted
in order to evaluate their quality according to BMJ
referees’s checklist [9] and it clearly showed that
the quality of vaccine economic evaluations needs
to be improved in terms of defining the viewpoint
of the analysis, the justification of the choice of
economic evaluation form, the explanation on the
choice of model and its parameters, the sources of
effectiveness and methods to evaluate health state
and  other  benefits  and  the  justification  of  the
choice of variables in the sensitivity analysis [10].
The public approach
In the field of vaccinations, the public, through
media  campaign  or  non-profit  organisations,
might  or  might  not  push  politicians  and
physicians to take action to address a perceived
health  problem  via  a  vaccine  [6].  Generally
speaking,  the  public  is  supportive  of
immunisation  programs  and  recognises  the
potential health benefits to individuals and to the
wider  society  of  high  rates  of  immunisation
coverage. However, there is a lot of evidence to
reinforce  the  fears  of  side-effects  and  concerns
over the safety of particular vaccines and as such
are  factors  associated  with  low  immunisation
coverage. 
A  study  was  conducted  to  explore  European
citizens’  opinions  on  the  extent  to  which
childhood  immunisation  should  be  a  matter  of
parental discretion or should be strictly enforced
by the State. In this study, barriers to childhood
immunisation include concerns over the risk of
adverse side-effects, distrust of those advocating
the  vaccines,  poor  communication  with  health-
care  staff  and  a  lack  of  awareness  of  the
immunisation schedule [11].
The  Health  Technology  Assessment  (HTA)
approach
This  approach  was  recently  developed  in
Europe  mainly  by  the  Danish  Center  for
Evaluation  and  Health  Technology  Assessment
(DACEHTA)  and  by  the  Health  Technology
Assessment  Public  Health  Unit  at  the  Catholic
University  in  Rome. The  starting  point  of  this
approach  was  to  consider  a  vaccine  as  a
technology.  In this field HTA is a multidisciplinary
tool that aims to examine the clinical, economic,
organizational, ethical, juridical, social and cultural
implications  of  the  introduction  or  the
implementation of a specific technology. HTA in
the field of vaccine has proved to be an innovative
and  effective  approach  in  order  to  support
decision-making processes, for the best allocation
of economic resources [12].
As an example of the application of the HTA
approach to the assessment of HPV vaccines [13-
14], the following issues were considered:
1.Epidemiological  evaluation  of  HPV  infection
and related diseases in Italy and in the world;
2.Study of health services utilisation from people
affected by HPV infection/diseases; 
3.Evaluation  of  current  measures  to  prevent
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cervical cancer (screening- PAP test);
4.Evaluation of HPV vaccines effectiveness;
5.Projecting a mathematical model to predict the
effects of new vaccine introduction;
6.Economical evaluation of vaccine introduction;
7.Determination of organisational concerns;
8.Study of ethical, social and legal impact.
This approach was confirmed very recently at
the  end  of  WHO  European  Region  Ministerial
Conference,  when  Health  Ministers  of  53
countries  adopted  the  Tallinn  Charter:  Health
Systems for Health and Wealth. HTA is identified as
important  means  to  create  resources  for  health
care  systems:  "...Fostering  health  policy  and
systems research and making ethical and effective
use  of  innovations  in  medical  technology  and
pharmaceuticals  are  relevant  for  all  countries;
health technology assessment should be used to
support more informed decision-making." [15]. 
Conclusion
In recent years, vaccinology has been one of the
scientific fields in which research has led to the
planning  and  implementation  of  several
biotechnological innovations. Now and more and
more in the next future, there will probably be
more vaccines on the market than those actually
used in daily public health life, and the value of a
new  vaccine  cannot  be  based  only  on
epidemiological  or  health  economical
considerations. What is required is a useful tool
capable of orientating not only decision makers,
but also researchers and citizens, towards a better
allocation  of  economic  resources.  HTA  is  a
multidisciplinary and politically oriented tool that
is capable of considering the clinical, economic,
organizational, ethical, juridical, social and cultural
implications  of  the  introduction  or  the
implementation  of  specific  technologies,  and,
among these, vaccines.
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